TRACON Pharmaceuticals Announces Results Based On Ongoing Double-Digit Objective Response Rate For Single Agent Envafolimab In The ENVASARC Phase 2 Pivotal Trial
Portfolio Pulse from Happy Mohamed
TRACON Pharmaceuticals announced positive results from the ongoing ENVASARC Phase 2 pivotal trial for single agent Envafolimab, with a double-digit objective response rate (ORR) and no > Grade 2 drug-related toxicity. The combination of Envafolimab with Yervoy did not show synergy and will be terminated, reducing trial costs and accelerating the timeline to final data.
June 20, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TRACON Pharmaceuticals' ongoing ENVASARC Phase 2 trial for single agent Envafolimab showed positive results with a double-digit ORR and no > Grade 2 drug-related toxicity. The combination with Yervoy will be terminated, reducing trial costs and accelerating the timeline to final data.
The positive results from the ongoing ENVASARC Phase 2 trial for single agent Envafolimab indicate that the drug is effective and well-tolerated, which is likely to boost investor confidence in TRACON Pharmaceuticals. The termination of the combination with Yervoy will reduce trial costs and accelerate the timeline to final data, which could also positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100